All Work

Chris Lange

Short Sellers Pile Into Cybersecurity Stocks

The April 29 short interest data have been compared with the previous figures, and short interest for the selected cybersecurity stocks increased.

Chris Lange · 10 years ago

Short Interest Remains Mixed on Major Oil

The short interest data have been released for the April 29 settlement date, and short interest for the selected oil stocks was ultimately mixed.

Chris Lange · 10 years ago

Short Sellers Back Off Major Semiconductors

The short interest data have come out for the April 29 settlement date. On the broad scope, short interest moves decreased in these semiconductor stocks.

Chris Lange · 10 years ago

Disney Stumbles Amidst Weak Earnings

The Walt Disney Co. (NYSE: DIS) reported fiscal second-quarter financial results after the markets closed on Tuesday. The company had $1.36 in earnings per share (EPS) on $12.97 billion in revenue compared to consensus…

Chris Lange · 10 years ago

Why Guidance Did Not Hold Back Electronic Arts Earnings

Electronic Arts Inc. (NASDAQ: EA) released its fiscal fourth-quarter earnings report after the markets closed on Tuesday. The company has $0.50 in earnings per share (EPS) on $924 million in revenue versus Thomson Reuters…

Chris Lange · 10 years ago

SolarEdge Sinks Despite Earnings Beat

SolarEdge Technologies reported better-than-expected fiscal third-quarter financial results after the markets closed on Monday.

Chris Lange · 10 years ago

What to Expect From Disney Earnings

Walt Disney is scheduled to report its fiscal second-quarter financial results after the markets close on Tuesday.

Chris Lange · 10 years ago

Rackspace Rises on Solid Earnings Beat

Rackspace Hosting, Inc. (NYSE: RAX) reported first-quarter financial results after the markets closed on Monday. The company had $0.37 in earnings per share (EPS) on $518 million in revenue compared to consensus estimates from…

Chris Lange · 10 years ago

Merus Announces Potential Pricing for IPO

Merus plans to offer more than 4 million shares within an expected price range of $14 to $16 per share in an initial public offering valued up to more than $79 million.

Chris Lange · 10 years ago

Theravance Gets FDA Nod on Vibativ

Theravance Biopharma has announced that the FDA approved its supplemental New Drug Application for Vibativ (telavancin) to expand the product's label.

Chris Lange · 10 years ago